Risk Assessment Strategy / Tools & Technology

Topic	Replies	Views	Activity
Carcinogenic Potency Database - Access free With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…	3	268	August 22, 2022
About the Risk Assessment Strategy / Tools & Technology category	0	82	April 14, 2021
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals	8	538	March 27, 2023
NDMA formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product Drug_Substance_APIs	0	62	March 24, 2023
Nitrosamines in topical products	3	174	March 9, 2023
Regulatory Highlights(OPR&D) featured	11	399	March 6, 2023
Formation of Dialkyl-N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation NDSRI	6	285	February 25, 2023
Anybody has working with a Gliclazide nitrosamine? Drug_Substance_APIs	3	257	February 14, 2023
IPEC Europe announces the availability of the revised “Questionnaire for Excipient Nitrosamines Risk Evaluation” (Version 4, 2022)	11	375	February 14, 2023
Lhasa Tutorial Vid on new Mirabilis 4.0	2	105	January 31, 2023
What to do with Nitrite content reported by Excipients?	0	241	January 25, 2023
Nitrosamines and bioequivalence studies	1	133	January 16, 2023
Nitrosamine Risk Assessment for Purified Water Used in Manufacturing for Pilot Bio/Clinical Trial Batches	1	109	December 5, 2022
What's your experience on API risk assessments?	4	126	November 25, 2022
N-nitrosoamides - a horse of a different color Drug_Substance_APIs	23	629	November 24, 2022
QSAR Toolbox - Free software. Any experience?	12	308	November 23, 2022
Checklist for EMA Q&A Q4	0	143	July 30, 2022
Berkeley Madonna	2	106	July 21, 2022
Fate purge study	0	80	July 14, 2022
Sufficient AMES test, parameters	6	250	July 13, 2022
Como conducir El Análisis de Riesgo?	0	69	May 9, 2022
What is the probability of nitrosamine formation during DP production	6	252	April 26, 2022
200+ USP Monograph w/ Tertiary amines	1	155	April 5, 2022
How Relevant is a 'check list'?	0	78	March 2, 2022
FDA Warning letter <Nitrosamine or NOT>	0	148	February 14, 2022
Update of the CMDh's Q&A Document on Nitrosamine Impurities	2	136	January 26, 2022
Nitrosamine Workshop USP / Sindusfarma / ANF ACFB -live discussion	7	343	December 8, 2021
When minimum information is provided for risk assessment?	1	91	November 23, 2021
Screening vs Risk Assessment?	11	198	September 7, 2021
Q&A Nitrosamine SAR working group (23 companies and universities)	12	262	August 25, 2021

Carcinogenic Potency Database - Access free

With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…